v3.21.1
Segment Information (Text Block)
3 Months Ended
Apr. 02, 2021
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company conducts its continuing operations through the Fabrication Technology and Medical Technology operating segments, which also represent the Company’s reportable segments.

Fabrication Technology - a leading global supplier of consumable products and equipment for use in the cutting, joining and automated welding, as well as gas control equipment, providing a wide range of products with innovative technologies to solve challenges in a wide range of industries.

Medical Technology - a leader in orthopedic solutions, providing devices, software and services spanning the full continuum of patient care, from injury prevention to joint replacement to rehabilitation.
Certain amounts not allocated to the two reportable segments and intersegment eliminations are reported under the heading “Corporate and other.” The Company’s management evaluates the operating results of each of its reportable segments based upon Net sales and segment operating income (loss), which represents Operating income (loss) before Restructuring and other related charges and European Union Medical Devices Regulation (“MDR”) and other costs.

The Company’s segment results were as follows:
Three Months Ended
April 2, 2021April 3, 2020
(In thousands)
Net sales:
     Fabrication Technology$568,128 $525,537 
Medical Technology311,083 290,819 
$879,211 $816,356 
Segment operating income (loss)(1):
     Fabrication Technology$82,305 $69,036 
Medical Technology2,162 3,804 
     Corporate and other(17,361)(14,078)
$67,106 $58,762 
(1) Following is a reconciliation of Income from continuing operations before income taxes to segment operating income:
Three Months Ended
April 2, 2021April 3, 2020
(In thousands)
Income from continuing operations before income taxes$35,647 $22,041 
Interest expense, net25,660 24,796 
Restructuring and other related charges(1)
4,046 11,025 
MDR and other costs(2)
1,753 900 
Segment operating income$67,106 $58,762 
(1) Restructuring and other related charges includes $1.8 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three months ended April 3, 2020, only.
(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017.